Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
0.8000
+0.0188 (2.41%)
At close: Jul 2, 2025, 4:00 PM
0.7996
-0.0004 (-0.05%)
After-hours: Jul 2, 2025, 7:59 PM EDT
Imunon Employees
Imunon had 25 employees as of December 31, 2024. The number of employees decreased by 8 or -24.24% compared to the previous year.
Employees
25
Change (1Y)
-8
Growth (1Y)
-24.24%
Revenue / Employee
n/a
Profits / Employee
-$711,728
Market Cap
17.04M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
IMNN News
- 14 days ago - IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 - GlobeNewsWire
- 15 days ago - IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ - GlobeNewsWire
- 4 weeks ago - IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study - GlobeNewsWire
- 4 weeks ago - IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS - GlobeNewsWire
- 5 weeks ago - IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 - GlobeNewsWire
- 5 weeks ago - IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 5 weeks ago - IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer - GlobeNewsWire
- 5 weeks ago - IMUNON Announces Withdrawal of Form S-1 Registration Statement - GlobeNewsWire